News, Scrip Scan

Glenmark Pharma down over 6%, hits 52-weeks low as FDA issues CRL for Ryaltris

Scrip Sanctuaries for protection from the wildlife in this jungle of Indian Equities

Glenmark Pharma down over 6%, hits 52-weeks low as FDA issues CRL for Ryaltris

Glenmark said it will continue to pursue regulatory approval for Ryaltris and work closely with the FDA to determine the appropriate next steps

Glenmark Pharmaceuticals plunged over 6 percent intraday on June 24, after the pharma player said the US Food and Drug Administration has issued a Complete Response Letter (CRL) regarding the new drug application for Ryaltris.

The CRL cites deficiencies in the Drug Master File pertaining to one of the active pharmaceutical ingredients and in manufacturing facilities, the company said in a regulatory filing.

At 1000 am, Glenmark was trading 6 percent down at Rs 469. The stock hit a fresh 52-week low at Rs 467.70 on the BSE.

“We would like to inform you that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application for Ryaltris (olopatadine hydrochloride [665 mcg] and mometasone furoate [25 mcg]), Nasal Spray,” Glenmark Pharmaceuticals said.

“The CRL does not specify any deficiencies with the clinical data supporting the New Drug Application for Ryaltris. We feel confident that we should be able to resolve these issues within the next six to nine months,” it added.

The company said it will continue to pursue regulatory approval for Ryaltris and work closely with the FDA to determine the appropriate next steps.

In a separate report, Glenmark said that it plans to partner with Novartis to promote, commercialize and distribute three respiratory products in Brazil. Novartis will be responsible for manufacturing the products and Glenmark will exclusively commercialise them in Brazil.

“A delay in Ryaltris approval (due to CRL issued by USFDA) will weigh on the stock until clarity emerges. The exclusive partnership arrangement will strengthen Glenmark’s respiratory franchise in Brazil,” said a Sharekhan note.

https://www.moneycontrol.com/news/business/markets/glenmark-pharma-usfda-crl-ryaltris-4129231.html

Excerpts from Gaurav’s Blog

Mumbai Equity Workshop ~ Saturday April 30 2022 ~ Almost Full ~ Top 10 Winning Moves

Losers Focus on Winners – Winners Focus on Winning   Workshop Conceptualised & Conducted by GAURAV A PARIKH Stock Markets ~ Minting Millions ~ TOP 10 Winning Moves Grabbing Short Term Too While Compounding Long Term Post Pandemic lock-down, this is the First Fundamental Direct Equity ‘Value Vs Price’ Workshop in over Two and a Half Years by Gaurav Parikh and Jeena … Mumbai Equity Workshop ~ Saturday April 30 2022 ~ Almost Full ~ Top 10 Winning Moves Read More » The post Mumbai Equity Workshop ~ Saturday April 30 2022 ~ Almost Full ~ Top 10 Winning Moves first appeared on Gaurav's Blog. [...]

RIP S T Gerela ex GM BSE ~ gave me the best compliment till date

  Rest in Peace now Gerela Saab  ! Mr S T Gerela ex GM of BSE passed away peacefully this morning We had not met in years but he always remained at the top of my mind when it came to testimonials for this is what he had said to me over a decade ago,when … RIP S T Gerela ex GM BSE ~ gave me the best compliment till date Read More » The post RIP S T Gerela ex GM BSE ~ gave me the best compliment till date first appeared on Gaurav's Blog. [...]

Vedanta de-listing offer price Rs 87.50~Come on Mr Anil Agarwal !

Vedanta de-listing offer price Rs 87.50~Come on Mr Anil Agarwal ! Promoter Group of  Vedanta Ltd has proposed a voluntary de-listing at an indicative offer price of Rs 87.50~are the over 7.3 lakh minority shareholders from Alibag !? …apologies to the people of Alibag Some would term this as De-listing Duplicity ~ but I would … Vedanta de-listing offer price Rs 87.50~Come on Mr Anil Agarwal ! Read More » The post Vedanta de-listing offer price Rs 87.50~Come on Mr Anil Agarwal ! first appeared on Gaurav's Blog. [...]

Riskless Reliance Industries Rights Investment Strategy

This is a Riskless Reliance Industries Rights Investment Strategy for those over 2.3 Million Shareholders already holding RIL shares. It is not a recommendation to buy RIL cum rights  It’s a no brainer yet I’m just penning a brief note because some have told me they hold Reliance but are skipping the Rights ! Don’t … Riskless Reliance Industries Rights Investment Strategy Read More » The post Riskless Reliance Industries Rights Investment Strategy first appeared on Gaurav's Blog. [...]

Covid-19 Crisis-Your Well Being is more important than Stock Market Well Being

 Wealth is negotiable, Health is not Your Personal Well Being is more important that the Stock Market Well Being ~ Always & more so in this unfathomable ongoing Covid-19 Reality Above’s a three minute reach out by me last night to all connected with me to reinforce this .It’s also posted on Facebook , … Covid-19 Crisis-Your Well Being is more important than Stock Market Well Being Read More » The post Covid-19 Crisis-Your Well Being is more important than Stock Market Well Being first appeared on Gaurav's Blog. [...]